Inclusion Criteria:  Female and 18-70 years old Metastatic or locally recurrent HER2-positive breast cancer Patients received pyrotinib-based therapy after lapatinib failure in treatment for metastasis Complete and accurate medical data  Exclusion Criteria:  - Incomplete medical data